Security Stocks; Visualant (OTCBB:VSUL) Spectral Pattern Matching Technology at International Security Conference & Exposition

SEATTLE - April 5, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions and an emerging leader in security and authentication systems technology will be demonstrating its Spectral Pattern Matching (�SPM�) technology at the booth of its wholly-owned subsidiary, TransTech Systems, Inc., at the International Security Conference & Exposition from April 6-8, 2011 at the Sands Expo & Convention Center in Las Vegas, NV.

The International Security Conference & Exposition (ISC West) is one of the fastest growing tradeshows in North America according to the publication Tradeshow Week. With over 23,000 industry professionals and 14,600 security buyers, ISC West is certainly the nation's largest security event of the year. ISC West will be hosting education sessions from April 5-7, 2011 as well as the exposition from April 6-8, 2011. See www.iscwest.com for more information.
Visualant's SPM technology sees color, nature's fingerprint, at the photon level. The SPM technology sees color the counterfeiter cannot see and provides an extra level of security against hacking in the important world of authentication.
See the Visualant SPM technology at TransTech's booth #22129.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Security Stocks; TransTech Systems, a Subsidiary of Visualant (OTCBB:VSUL), to Exhibit at the International Security Conference & Exposition

SEATTLE - March 31, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems will be exhibiting at the International Security Conference & Exposition from April 6-8, 2011 at the Sands Expo & Convention Center in Las Vegas, NV.

The International Security Conference & Exposition (ISC West) is one of the fastest growing tradeshows in North America according to the publication Tradeshow Week. With over 23,000 industry professionals and 14,600 security buyers, ISC West is certainly the nation's largest security event of the year. ISC West will be hosting education sessions from April 5-7, 2011 as well as the exposition from April 6-8, 2011. See www.iscwest.com for more information.
TransTech Systems (www.ttsys.com) will be exhibiting the latest in identification card printing and encoding systems and building access control products from manufacturers such as Evolis, NiSCA, FarPointe, and Datacard. TransTech also will be demonstrating the new Visualant Spectral Pattern Matching technology. See these and other popular security industry products on display in TransTech's booth #22129.
We will post this press release on the Visualant website at www.visualant.net. If we have an email address for you, we will send you a copy of our press releases electronically. We want to remind you that if you have not already done so, please enter your email and other information on the form on the website at: http://visualant.net/contactus.html.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Biodefense Stocks /Homeland Defense Stock Alert; Dynasil Corporation (NASDAQ GM: DYSL) trading at $6.26, up 2.50 (66.49%)

Radiation Fears and Biological Warfare Threats Raise Investor Interest in Biodefense Stocks;
(OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (NasdaqGM: SIGA )

Point Roberts, WA- March 23, 2011 - Investorideas.com, a leader in investor sector research
including Homeland Defense and Biodefense Stocks issues a trading alert on the sector as
Dynasil Corporation of America(NasdaqGM: DYSL ) becomes the top gainer on the NASDAQ on
patent news for its radiation monitoring device.

Dynasil Corporation (NASDAQ GM:DYSL), announced today that its research division, Radiation
Monitoring Devices, Inc. (RMD), also of Watertown, was granted additional U.S. patent claims for
advances in a detector material capable of responding independently to both neutron and gamma
radiation. This advancement is of critical national importance because the most commonly
available technology for detecting neutrons in Homeland Security applications, specifically
neutron detectors based on gaseous Helium-3, is becoming impractical because of serious
limitations on the availability of this gas.



In a recent article on Daily Finance entitled “Inside Wall Street: Looking to the Bio-Defense
Sector as Nuclear Fears Mount”, notes - The sector attracted a lot of interest after 9/11 and a
number of companies emerged to develop protective biodefense drugs and products. But with the
waning of dark headlines about terrorist threats, investors have tended to put them on their low-
priority list.
That may be about to change

Full article : http://www.dailyfinance.com/story/stock-picks/inside-wall-street-looking-to-bio-defense-sector-as-
nuclear-fea/19880106/

Biodefense Stocks Sector Snapshot
Aethlon Medical (OTCBB: AEMD) trading at $0.14
Dynasil Corporation (NASDAQ GM: DYSL) trading at $6.26, up 2.50 (66.49%) 12:21PM EDT
Emergent Biosolutions, Inc. Com (NYSE: EBS ) trading at $23.53, down 0.04 (0.17%) 12:29PM
EDT
PharmAthene, Inc. (NYSE Amex: PIP) trading at $3.42, up 0.01 (0.29%) 12:27PM EDT
Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) trading at $0.32
Siga Technologies (NasdaqGM: SIGA ) trading at $12.27, up 0.25 (2.08%) 12:29PM EDT

Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp

Biodefense Company Snapshot

Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer.
Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in
disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious
viruses and immunosuppressive proteins from the entire circulatory system. We recently
discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune
system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly
inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in
cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet
clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or
interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com

Visit the Aethlon Medical ( OTCBB:AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD

Get added to the company’s news alerts:
http://www.investorideas.com/Resources/Newsletter.asp

About InvestorIdeas.com:

InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector
investing, including biotech stocks with its portal BiotechIndustryStocks.com.

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make

recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated
by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD )
Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five
thousand per month in 144 stock)Effective March 15, 2011
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially
different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

Biodefense Stocks Snapshot; (OTCBB: AEMD), (NasdaqCM: CBLI), (NYSE Amex: PIP), (NasdaqGM: SIGA)

Point Roberts, WA - March 22, 2011 - Investorideas.com, a leader in investor sector research including biotech and biodefense stocks looks at some of the biotech stocks developing technologies and products to deal with news headlines of �radiation leaks and biological warfare�. Biodfense stocks have not been in the investor spotlight in recent years as Bioterrorism fears subsided and new issues took the forefront for Wall Street.

A major trigger for the sector are the global concerns and fears that Libyan leader, Colonel Muammar Gaddafi will potentially use biological and chemical weapons.
In a recent article on Daily Finance entitled "Inside Wall Street: Looking to the Bio-Defense Sector as Nuclear Fears Mount", notes - The sector attracted a lot of interest after 9/11 and a number of companies emerged to develop protective biodefense drugs and products. But with the waning of dark headlines about terrorist threats, investors have tended to put them on their low-priority list.
That may be about to change
Full article : http://www.dailyfinance.com/story/stock-picks/inside-wall-street-looking-to-bio-defense-sector-as-nuclear-fea/19880106/
Following 911, Project Bioshield Act was passed by Congress in 2004 calling for $5 billion for purchasing vaccines to be used in the event of a bioterrorist attack. Biotech companies continued to move forward with solutions as investors moved on to other sectors.
According to a recent article in Bioprepwatch.com, "Bioterrorism, in my view, is the most serious and likely threat to our national security, "Simon said, SNCTimes.com reports.
Full article : http://www.bioprepwatch.com/news/236579-expert-warns-of-bioterrors-ability-to-undermine-america
Chairman and CEO of Aethlon Medical, Inc.(OTCBB: AEMD) recently updated his shareholders regarding their biodfense efforts in letter March 15 th .
"As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats."
Mr. Joyce went on to say, :Earlier this year, we were honored to be invited by The Department of Health and Humans Services (HHS) to present our Hemopurifier® as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. "
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, reported last month " that new pharmacokinetic data from the Company's Valortim® anthrax anti-toxin program were presented at the 9th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Washington, DC, February 6-9, 2011. The data were presented by Dr. Elizabeth Leffel, Director of Non-Clinical Sciences for PharmAthene, in a poster presentation entitled, "Pharmacokinetics of a Monoclonal Anthrax Anti-Toxin Antibody in Healthy and Infected Cynomolgus Macaques."
Biodefense Stocks Sector Snapshot

• Aethlon Medical (OTCBB: AEMD) trading at $0.14
• Cleveland BioLabs (NasdaqCM: CBLI ) trading at $7.35, up 0.19 (2.65%) 10:10AM EDT
• Emergent Biosolutions, Inc. Com (NYSE: EBS ) trading at $23.59, up 0.02 (0.08%) 10:33AM EDT
• PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, trading at $3.42, up 0.01 (0.29%) 10:31AM EDT
• Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) trading at $0.33
• Siga Technologies (NasdaqGM: SIGA ) trading at $11.83, down 0.28 (2.31%) 10:35AM EDT
• Soligenix, Inc. (OTCBB:SNGX) trading at $0.20

Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp
Market Snapshot

• Dow 12,027.75 -8.78 -0.07%
• NASDAQ 2,690.32 -1.77 -0.07%
• S&P 500 1,296.45 -1.93 -0.15%
• 10 Yr Bond(%) 3.3390% +0.0160
• Oil 102.45 +0.13 +0.13%
• Gold 1,426.20 0.00 0.00

Biodefense Company Snapshot
Aethlon Medical ( OTCBB:AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Visit the Aethlon Medical ( OTCBB:AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011     
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

Security Stocks; Visualant (OTCBB:VSUL) Subsidiary TransTech Systems Obtains Exclusive Department of Homeland Security Distribution Deal

SEATTLE - March 22, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color-based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems has become the exclusive distributor to the US Federal Government of a new custom-developed proximity card programmer for use on their newly mandated identification cards.

This programmer will allow those agencies to program both 125 kHz and 13.56 MHz access control cards to match the current format in use at any particular facility, and will eliminate the expense for those agencies to have the cards individually programmed by the proximity chip manufacture prior to delivery. Agencies can now order standard card stock for all their facilities and not be required to purchase different formats for different locations as necessary prior to the development of this new device. As well, this offering will allow more flexibility in time and budget to the many agencies that are being forced to consider expensive upgrades to their existing access control systems in order to comply with the HSPD-12 presidential directive that all federal employees carry a specific type of access card, referred to as Personal Identity Verification ("PIV").
Jim Gingo, TransTech President stated, "This product will be supplied to the Department of Homeland Security ("DHS") on an exclusive basis. This order is indicative of our ongoing commitment to and support of the many DHS agencies with which we work with the ultimate goal of assisting them to save money and better work within the constraints of severely reduced funding."
Ron Erickson, Visualant CEO said, "TransTech has a respected reputation for excellence in the security and authentication marketplace. The work that Jim Gingo and his team perform for our nation’s government is first rate and helps provide the security that we demand for our country."
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Ronald Erickson, CEO, of Visualant Inc. (OTCBB: VSUL), Discusses the Power and Accuracy of its Patent Pending Sensor Technology

Published at (www.investorideas.com defense stocks blog ) Research defense and Homeland Security stocks with the largest global defense stocks directory online for investors at Investorideas.com and www.Homelanddefensestocks.com click here: http://www.investorideas.com/Companies/HomelandDefense/Stock_List.asp Defense and security companies - Become a showcase defense stock at www.investorideas.com and www.homelanddefensestocks.coMultiple Market Applications For Spectral Pattern Matching Technology Include Homeland
Security, Identity Theft, Environmental and Agricultural

Point Roberts, WA- March 22, 2011 – Investorideas.com, an investor research portal
specializing in sector research, including security stocks, presents a Q&A interview featuring Mr.
Ronald Erickson, CEO, President and Chairman of the Board of Visualant, Inc. (OTCBB:VSUL).

Visualant’s patent pending ‘Spectral Pattern Matching’ technology uses light to create a unique
signature for individual items and classes of items, including a recent environmental application to
identify oil in water.

Interview:

Q: Investorideas.com
Ron, according to your corporate description, your sensor technology offers the simplest, fastest
and most inexpensive means to document unique non-visible signatures from nearly any kind of
product or surface. What kind of results and feedback are you seeing with the technology as your
applications widen into new markets?

A: Ronald Erickson, CEO, President and Chairman of the Board

As we continue our work in the laboratory we are discovering some rather startling results. For
example, this past week we were able to differentiate between ten brands of vodka. I don’t
expect that to be a business focus for us. It simply illustrates the power of the Spectral Pattern
Technology to detect the unique differences that exist between substances that appear identical
to the human eye.

Q: Investorideas.com
With some of the most recent applications in conjunction with your licensed partner, Javelin LLC,
you are detecting oil in water. To what level of accuracy and to what degree can your technology
detect the oil?

A: Ronald Erickson, CEO, President and Chairman of the Board

In the laboratory test setting we have been able to detect miniscule amounts of oil or adulterates
in oil. The laboratory tests have provided evidence of an acceptable level of accuracy.

Q: Investorideas.com
From an accuracy and efficiency standpoint, who would you say your nearest competitors are in
the sensor market? And how do you compare?

A: Ronald Erickson, CEO, President and Chairman of the Board

There are any number of competitors providing competitive products in the senor market. We
believe that we have a distinct competitive advantage because of our low cost model and the
flexibility and durability of our technology.

Q: Investorideas.com
How does your technology enhance and improve overall security by adding it to current
biometrics technology?

A: Ronald Erickson, CEO, President and Chairman of the Board

The Visualant Spectral Pattern Technology adds an additional layer of authentication and
requires no added features such as an RFID chip, taggant, thread or hologram. We simply see
that color that is present.

Q: Investorideas.com
In terms of new applications, is there ongoing testing and R&D to develop new markets internally
at Visualant or do you work with partners and companies that license the technology to build this
out ?

A: Ronald Erickson, CEO, President and Chairman of the Board

We do both. We are working on a Spectral Pattern Matching Development Kit which third parties
can use to develop their own applications. We are also working on some product ideas at
Visualant which we will bring to market ourselves and in conjunction with joint venture partners.

Q: Investorideas.com
In terms of potential new partners and markets, what industry sector are you seeing the most
interest and activity in? And why do you think that is?

A. Ronald Erickson, CEO, President and Chairman of the Board

Naturally, given the focus of our TransTech subsidiary on the security and authentication
marketplace we are seeing most of our activity in that sector. It is an extremely important part of
the market.

About Visualant, Inc. (OTCBB: VSUL)
Visualant, Inc. develops low-cost, high speed, light-based security and quality control solutions
for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and
process control applications. Its patent-pending technology uses controlled illumination with
specific bands of light, to establish a unique spectral signature for both individual and classes
of items. When matched against existing databases, these spectral signatures allow precise
identification and authentication of any item or substance. This breakthrough optical sensing
and data capture technology is called Spectral Pattern Matching (SPM). SPM technology can be
miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and
can be combined in the same package as a bar-code or biometric scanner. www.visulant.net

Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security
and authentication solutions to security and law enforcement markets throughout the United
States. www.ttsys.com

Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net

Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visit the company profile on Investorideas.com
http://www.investorideas.com/CO/VSUL/

About InvestorIdeas.com:

InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector
investing, covering leading industry sectors including defense stocks, energy stocks, mining and gold
stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com
is known for its comprehensive stock directories in each sector and sector specific newswires.

Get investor alerts for VSUL:

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer:
This news is paid for as part of the showcase advertising program for Visualant, Inc. (OTCBB: VSUL)
Visualant is a featured showcase company on Investorideas.com and related security portals and blogs.
The cost for this service is Two thousand five Dollars per month which has been paid by a third party. Our
sites do not make recommendations, but offer information portals to research news, articles, stock lists and
recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products
or securities. All information on showcase companies is taken from public documents, news, filings and
the company website and management. This site is currently compensated by featured companies, news
submissions and online advertising. Investors are reminded all investment involves risk including possible
loss of principal. Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Contact Investorideas.com
dvanzant@investorideas.com 800 665 0411m for as little as $1000 month

Biodefense Stocks; Aethlon Medical (OTCBB:AEMD) Discusses Device Opportunity To Treat Sepsis and Bioterror Threats

San Diego, CA, March 16, 2011 � Investorideas.com newswire; Biotech and biodefense stock news; Aethlon Medical Shareholder Letter Aethlon Medical, Inc., (OTCBB:AEMD) disclosed that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.
Website: aethlonmedical.com

To our Shareholders:
As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats. This policy shift redefines the primary strategic objective of related government agencies to be the identification and support of innovative broad-spectrum countermeasures, technologies, and platforms. This is a considerable shift from the government�s previous focus of attempting to align a single drug or vaccine countermeasure with each pathogen threat. We remain convinced that our Hemopurifier� is the most advanced broad-spectrum countermeasure, technology, or platform.
Earlier this year, we were honored to be invited by The Department of Health and Humans Services (HHS) to present our Hemopurifier� as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. While the pursuit of government grants and contracts is not our primary focus, it is difficult to ignore a growing pipeline of new and evolving opportunities to advance our science with non-dilutive capital resources.
On February 8th, we were pleased to learn that the Defense Advanced Research Projects Agency (DARPA) released a broad agency announcement (BAA) entitled: �Dialysis Like Therapeutics� (DLT). The goal of the DLT program is to develop a portable device that removes �dirty� blood from the body, separates harmful agents, and returns �clean� blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine, the target application for this device is sepsis. The envisioned device will be capable of removing at least 90% of unknown pathogens, toxins, and activated cells from a patient in one day. As stated in the BAA, targets for removal include viral pathogens referenced to include Hepatitis-C Virus (HCV), Human Immunodeficiency Virus (HIV), Influenza Bio-agents, Smallpox, and viral hemorrhagic fevers. As we have proven capabilities within the scope of this BAA, we plan to respond with a full proposal by April 1st.
If you are not familiar with DARPA, their mission is to maintain the technological superiority of the U.S. military and prevent technological surprise from harming our national security by sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military use. Innovation sponsored by DARPA has resulted in groundbreaking discoveries and life changing advances such as the internet. DARPA envisions that the device developed under this BAA would save the lives of thousands of military patients each year.
If selected to participate in the DLT program, we would anticipate a multifaceted role that would involve teaming with other industry partners to advance our core Hemopurifier� as an innovative dialysis-like multi-use platform technology able to selectively target deleterious pathogens and toxins from the entire circulatory system. We would also seek expand the capabilities of our technology platform as the basis for a device targeting to reduce the presence of circulating factors that are precursors to sepsis. Our goal would be to reduce the occurrence of sepsis as post-sepsis treatment strategies to inhibit the inflammation process including the modulation of inflammatory cytokines have yet to be proven clinically beneficial. It is also possible that we could participate in the advancement of portable blood pump technology required under the BAA that would be deployed to treat wounded warfighters with extracorporeal device technologies including current and future iterations of our Hemopurifier� technology. Regardless of outcome, it is truly gratifying to witness therapeutic filtration being the focal point of a government contract opportunity. This is especially true when it comes from an agency as scientifically adept as DARPA. Once we complete our submission to DARPA, I will be back in touch with an update on other activities.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier� to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company�s ability to raise capital when needed, including obtaining government grants, the Company�s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier� to improve the efficacy of SOC therapy against HCV, the Company�s ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier�, the impact of government regulations, patent protection on the Company�s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company�s Securities and Exchange Commission filings.
Disclaimer /Disclosure
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Visit the profile at Investorideas.com: http://www.investorideas.com/co/aemd/